We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Halozyme Therapeutics Incorporated | NASDAQ:HALO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.42 | 1.09% | 38.88 | 37.13 | 43.00 | 39.02 | 38.44 | 38.46 | 547,134 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit on Friday said is seeking approval from the European Medicines Agency for subcutaneous use of Darzalex in patients with multiple myeloma.
Darzalex is currently only approved for intravenous use.
Janssen said subcutaneous Darzalex is co-formulated with Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery technology.
Janssen last week filed for U.S. Food and Drug Administration approval for the subcutaneous formulation of Darzalex in multiple myeloma, a cancer that forms in a type of white blood cells called plasma cells and causes cancer cells to accumulate in the bone marrow.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Halozyme Therapeutics Chart |
1 Month Halozyme Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
